Lanoxin MD

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanoxin MD

What is Lanoxin MD? (Digoxin)

Property Description
Active ingredient Digoxin
Form Tablet (Oral formulation), Injectable solution
Pharmacological class Cardiac Glycoside, Positive Inotrope
General purpose To strengthen the heartbeat and control rhythm
Origin Derived from the Digitalis lanata plant

What is Lanoxin MD and How is it Classified?

Lanoxin MD is a specific prescription-only medicine that contains the active ingredient Digoxin, a potent substance formally classified as a cardiac glycoside. This classification identifies it as a specialized drug within cardiovascular pharmacology, primarily acting as a positive inotrope and an antiarrhythmic agent. This means the medication belongs to a specific group of agents that directly influence the mechanical and electrical activity of the heart muscle, a function clinically recognized for decades in managing specific chronic heart conditions. Digoxin is utilized to specifically affect the strength and rhythm of the heart. Digoxin is an established therapeutic agent used to support and regulate the function of a heart requiring increased pumping strength and controlled rhythm.

Composition and Origin: Is Digoxin Natural or Synthetic?

The Digoxin active ingredient in Lanoxin MD is a naturally derived compound, specifically a cardenolide glycoside purified from the leaves of the Digitalis lanata plant. Digoxin possesses the molecular formula C41H64O14 and is categorized as a cardenolide. This substance is administered as a single-agent product, containing only Digoxin as the active component. Its origin as a plant-derived agent has been established for centuries. While most commonly formulated as an oral formulation in tablet form, the medicine is also available as an injectable solution for rapid, specialized administration.

What is the General Purpose of Lanoxin MD?

The general purpose of Lanoxin MD is to enhance the functional capacity of the heart by simultaneously strengthening its contraction and regulating its speed. Its underlying mechanism principle is to produce a positive inotropic effect—an increase in the force of the heart muscle—while promoting a controlled, slower heart rate. This combined action helps the heart pump blood more powerfully and efficiently throughout the body. The fundamental benefit is supporting the maintenance of adequate blood circulation and establishing a more stable, controlled heart rhythm, typically used in the context of improving the heart's pumping efficiency.

What side effects are possible with Lanoxin MD?

Possible side effects and safety information

The safety profile of Lanoxin MD (Digoxin) is officially documented by regulatory agencies, reflecting its narrow therapeutic index. This means the difference between concentrations needed for therapeutic effect and those causing toxicity is small, primarily impacting the heart's electrical system and the gastrointestinal tract.


Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized by frequency in official documentation:

  • Common events (occurring in 1/100 to 1/10 patients) include various arrhythmias and conduction disorders (such as sinus bradycardia and PR prolongation), along with gastrointestinal disturbances (nausea, vomiting, diarrhoea), dizziness, and visual impairment (e.g., blurred or yellow vision).
  • Uncommon events include depression.
  • Very Rare events (less than 1/10,000) include more serious conditions like thrombocytopenia, psychotic disorder, and intestinal ischaemia or gastrointestinal necrosis.

Clinically Significant Safety Considerations

The most clinically important serious adverse reaction is cardiac toxicity, which can manifest as nearly any type of arrhythmia or conduction abnormality. Manifestations of toxicity often involve a combination of cardiac, visual, and gastrointestinal symptoms.

  • Population-Specific Safety: Regulatory labeling notes that geriatric patients and those with renal impairment require particular attention, as the drug's primary clearance by the kidneys means impaired function leads to increased exposure. In pediatric patients, toxicity may present as sinus bradycardia rather than common adult symptoms like nausea.
  • Physiological Constraints: Official documents explicitly state that the risk of toxicity is increased by electrolyte imbalances, specifically hypokalemia (low potassium), hypomagnesemia, and hypercalcemia (high calcium). These conditions are documented to heighten the drug's effect.

Overdose and Emergency Response

Overdose and When to Seek Help

Lanoxin MD (digoxin) toxicity occurs when the amount of medicine in the body is too high. Because the therapeutic dose is close to the toxic dose, it is vital to be aware of the signs of overdose.

System Affected Common Manifestations
Gastrointestinal Loss of appetite (anorexia), nausea, vomiting, or persistent diarrhea.
Central Nervous System Confusion, weakness, or changes in vision (such as blurred or yellow/green vision).
Cardiac (Heart) Changes in heart rate or rhythm, such as an irregular, fast, or very slow heartbeat.

When to Seek Immediate Medical Attention

If you experience any of the signs of toxicity listed above, you must stop taking Lanoxin MD and contact your healthcare provider immediately for guidance.

In cases of accidental or suspected overdose, call emergency services or a Poison Control center right away. Overdose can be life-threatening and requires prompt treatment.

Factors That Increase Risk

Certain factors can increase the risk of toxicity, even if the prescribed dose is taken correctly. These include:

  • Impaired kidney function.
  • Electrolyte imbalances, particularly low potassium (hypokalemia) or low magnesium levels.
  • Advanced age or low body weight.

It is essential to have regular blood tests to monitor drug levels, kidney function, and electrolytes while taking this medication. In infants and small children, changes in heart rate and rhythm are often the earliest and most frequent signs of toxicity.

Therapeutic Uses of Lanoxin MD

What Lanoxin MD Treats

Lanoxin MD (digoxin) is a medication primarily used to manage specific heart conditions. It belongs to a class of drugs known as cardiac glycosides, which work by affecting the minerals (sodium and potassium) inside heart cells. This process helps the heart function more efficiently.

Main Uses

Heart Failure Lanoxin MD is frequently prescribed for the long-term management of chronic heart failure. In this condition, the heart muscle is unable to pump enough blood to meet the body's needs. The medication helps by increasing the force of the heart's contractions, allowing it to circulate blood more effectively throughout the body.

Atrial Fibrillation and Flutter The medication is also used to treat certain types of irregular heart rhythms (arrhythmias), specifically those originating in the upper chambers of the heart, such as atrial fibrillation and atrial flutter. It helps to slow down the heart rate when it is beating too fast or irregularly, improving the overall stability of the heart's rhythm.

Benefits and Goals of Treatment

  • Improved Pumping Efficiency: By strengthening the heartbeat, Lanoxin MD helps the heart move more blood with each contraction.
  • Symptom Management: For individuals with heart failure, effective treatment can lead to a reduction in common symptoms such as shortness of breath and swelling in the ankles or feet.
  • Heart Rate Control: In cases of rapid heart rhythms, the medication helps maintain a more stable and resting heart rate, which can reduce the feeling of heart palpitations.
  • Exercise Tolerance: By improving cardiovascular efficiency, patients may find they have more stamina for daily physical activities.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lanoxin MD

Lanoxin MD (Digoxin) eligibility is strictly defined by government regulatory documents, classifying populations into allowed, restricted, and contraindicated groups.

Allowed Populations: Use is established for adults and pediatric patients requiring treatment for the labeled cardiac conditions. Use in older adults is permitted but warrants additional caution due to the higher prevalence of decreased renal function.

Absolute Contraindications (Must Not Use): The medication is strictly contraindicated in patients with Ventricular fibrillation and those with a known history of Digoxin toxicity. Use is also prohibited in patients with certain structural heart conditions, such as Hypertrophic obstructive cardiomyopathy, as outlined in official labeling.

Conditional and Restricted Use: Eligibility is conditional for patients with severe renal impairment; official labeling requires careful monitoring. Use is also restricted in cases of Wolff-Parkinson-White Syndrome with atrial fibrillation and is generally not recommended immediately following an Acute myocardial infarction. During pregnancy and lactation, use is permitted only if the potential benefit outweighs the potential risk.

What should I know about interactions with other medicines?

Lanoxin MD (digoxin) has a narrow therapeutic window, meaning the difference between an effective dose and a potentially toxic dose is small. Consequently, numerous medications and substances can significantly alter the concentration of digoxin in the blood or increase the risk of adverse effects, making careful monitoring essential.

Interactions generally fall into two categories: those that increase digoxin levels (raising toxicity risk) and those that decrease digoxin levels (reducing therapeutic effect).

Medications that may increase Digoxin levels (Risk of Toxicity)

Certain drugs can inhibit the elimination of digoxin from the body, leading to a buildup. These often require a digoxin dose reduction and close monitoring:

  • Antiarrhythmics: Amiodarone, Propafenone, Quinidine
  • Calcium Channel Blockers: Verapamil, Diltiazem
  • Antibiotics: Clarithromycin, Erythromycin, Tetracycline, Trimethoprim
  • Diuretics: Spironolactone

Medications and Products Affecting Digoxin Levels

Interaction Type Examples of Interacting Agents
Decrease Digoxin Absorption Antacids (aluminum/magnesium salts), Kaolin/Pectin, Cholestyramine, High-fiber meals/supplements
Increase Digoxin Elimination St. John's wort (herbal supplement), Rifampicin
Increase Risk of Toxicity Diuretics (e.g., Furosemide) that cause low potassium or magnesium levels (hypokalemia/hypomagnesemia)

Always inform your healthcare provider of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), for instance, may increase the risk of digoxin toxicity by impairing kidney function.

Mechanism of Action

Enzyme Inhibition and Increased Heart Muscle Strength

Lanoxin MD (Digoxin) acts primarily by inhibiting the Sodium-Potassium ATPase Pump ( Na^+/ K^+-ATPase) on cardiac muscle cells. This inhibition raises intracellular sodium ( Na^+) concentration, which subsequently slows the Sodium-Calcium Exchanger (NCX). The resulting net increase in intracellular calcium ( Ca^2+) leads directly to increased force of myocardial contraction ( positive inotropy).

Autonomic Modulation for Electrical Rhythm Control

Simultaneously, the mechanism involves an enhancement of parasympathetic nerve activity (vagal tone) which targets the heart’s conduction system. This modulation slows the transmission of electrical impulses across the Atrioventricular (AV) node. This action produces a slowing of the electrical conduction velocity ( negative dromotropy), acting alongside the effect on contractility.

Potassium and Mechanistic Constraints

The mechanism is constrained by extracellular potassium ( K^+) concentration. Since K^+ competes with Digoxin for the same binding site on the Na^+/ K^+-ATPase enzyme, high K^+ levels can reduce the drug's binding affinity and subsequent efficacy.

Dosage and Administration Information

Instructions for Using Lanoxin MD (Digoxin)

The administration of Lanoxin MD involves dosing that is personalized according to the patient’s lean body weight and kidney function (Creatinine Clearance).

Administration and Route

Type Details
Route of Use Primarily Oral (tablet or solution) for routine daily use. The Intravenous (IV) route is used when a rapid therapeutic effect (digitalization) is necessary.
Dosage Forms Tablets are available in strengths such as 0.0625 mg, 0.125 mg, and 0.25 mg. The injectable solution is also available for IV use.
Frequency Maintenance doses are typically administered once daily. The initial loading dose is given in divided fractions over 24 hours to establish adequate levels quickly.

Dosing Regimens

Standard Adult Maintenance Dose: The common range is 0.125 mg to 0.25 mg (125 mcg to 250 mcg) once daily. Dosage adjustments, if necessary, are generally not made more often than every two weeks, allowing the drug to reach a consistent level.

Population-Specific Rules:

  • Renal Impairment: A mandatory dose reduction is required in patients with reduced kidney function, as elimination is primarily renal. Dosing is often calculated using estimated Creatinine Clearance.
  • Older Adults: Lower doses are often needed, determined by lean body weight and an assessment of kidney function.
  • Pediatric Patients (lt 10 years): Dosing is complex, based on age and lean body weight, and is typically administered twice daily for maintenance.

Contextual Use Instructions

  • With/Without Food: Tablets may be taken with or without food, though consistency in timing is advised. High-fiber meals may reduce the total amount absorbed from the oral form.
  • IV Administration: Intravenous doses must be administered slowly over a period of 5 minutes or longer; rapid bolus injection is avoided. The IV dose is typically 20% to 25% lower than the oral dose to account for differences in absorption.
  • Missed Dose: If a dose is missed, it should generally be omitted, and the next scheduled dose should be taken at the usual time; do not double doses to compensate for a missed dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Lanoxin MD

Evidence for Use in Chronic Heart Failure

Research for the evaluation of Lanoxin MD (digoxin) in Chronic Heart Failure (CHF) has primarily centered on large-scale clinical studies. The core evidence base includes long-term Randomized Controlled Trials (RCTs) that included control groups for evaluation in adults with symptomatic chronic heart failure. These studies focused on measuring how often patients were admitted to the hospital specifically for heart failure and how daily functioning evolved during the observation periods.

One large RCT reported patterns observed in all-cause mortality over several years, describing a neutral finding when comparing the groups studied. Other retrospective analyses suggest that observed patterns may be associated with certain patient factors recorded in the trials, such as specific measured concentration levels. The discussion on all-cause mortality in CHF remains an area where certainty remains low.


Evidence for Use in Chronic Atrial Fibrillation

The evidence for the evaluation of Lanoxin MD in Chronic Atrial Fibrillation (AFib) is largely based on systematic reviews and observational studies, which differ from the design of large RCTs. Studies in this area primarily examined outcomes related to physical discomfort and monitored physiological strain, focusing on the ability to control the heart rate at rest.

Findings describe patterns observed in observational studies monitoring outcomes over several years. These findings were mixed across different reports; some research was associated with a higher observed risk of mortality, while other analyses did not report this association. There is a research limitation as there is a lack of dedicated, long-term, contemporary RCTs designed to evaluate the impact on all-cause mortality in patients with AFib alone. Evidence quality varies, and data are still emerging.


Long-Term Studies and Follow-Up Duration

Studies exploring the evaluation of the medicine have utilized follow-up durations that vary widely, ranging from short-term assessments to trials that monitored patients for several years. The largest studies offer comprehensive information regarding the long-term course of the medicine’s effects, with follow-up durations of approximately three to four years.

Research highlights changes measured during these defined time intervals, and the evidence contributes to understanding symptom patterns over time. However, there is limited information for outcomes that extend beyond the main follow-up periods of the key trials. Therefore, the long-term effects on all outcomes are not fully established beyond the time frame covered by the largest studies.


Research in Specific Patient Groups

Research has explored the evaluation of the medicine across different adult populations with heart conditions. Studies were evaluated in patients with Chronic Heart Failure presenting with varying degrees of functional limitations, including those with a reduced or preserved heart pumping strength. For certain populations, such as pediatric patients, data for certain groups remain insufficient. Findings describe group patterns from the populations studied, but these research reports do not determine whether an individual in any specific group will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Lanoxin MD (FAQ)

Q: What are the early signs that might indicate Lanoxin MD levels are too high (potential toxicity)?

Official product information reports signs associated with high levels of the medicine, which requires careful management. These early signs may include non-specific symptoms such as confusion, loss of appetite, nausea, vomiting, and diarrhea.

Changes to vision or heart rhythm can also occur and are part of the manifestations associated with potentially high levels of the medicine.


Q: What kind of vision changes are possible with Lanoxin MD?

Reported vision changes include visual impairment such as blurred vision or the appearance of yellow vision.

This yellowing is described in regulatory documents as an aberration in color vision, often with a predominance of yellow-green hues.


Q: Is it true that mental changes like confusion or depression can be associated with Lanoxin MD?

The medicine has been associated with effects on the central nervous system (CNS). Reported effects include common events like dizziness and less common events such as depression and confusion.

More rare effects such as delirium and psychotic disorder have also been observed.


Q: Are yellow or green halos around lights a possible side effect of Lanoxin MD?

Official documentation does not typically use the term 'halos around lights.' However, the product information does describe the possibility of color vision aberration and yellow vision as common adverse events.

These visual changes involve a predominance of yellow-green colors and may also manifest as blurred vision.


Q: Is there a possibility of developing a skin rash while taking Lanoxin MD?

Yes, a skin rash is reported among the side effects that have been observed with the use of the medicine.


Q: Are there any herbal supplements that are known to interact with Lanoxin MD?

The herbal supplement St. John's wort is officially listed as an agent that can increase the body's elimination of the medicine, potentially reducing its effectiveness.

Official guidance recommends informing your healthcare provider about all prescription drugs, over-the-counter medicines, and any herbal products being taken.


Q: Can people with kidney problems still use Lanoxin MD?

Use is permitted in patients with kidney problems, but use warrants careful monitoring. Official labeling mandates a dose reduction and careful monitoring of kidney function, as the medicine is primarily cleared from the body by the kidneys.


Q: Can Lanoxin MD be used in children and infants (pediatric patients)?

Use of the medicine is officially established for pediatric patients (children and infants). However, dosing is complex and strictly based on the patient's age and lean body weight.


Q: What does the medical literature say about Lanoxin MD use in patients who have recently had a heart attack?

Official labeling indicates that use is generally not recommended immediately following an Acute myocardial infarction (a heart attack).


Q: What kind of studies have been conducted on the long-term outcomes of using Lanoxin MD for heart failure?

The evaluation of the medicine for chronic heart failure has involved large-scale Randomized Controlled Trials (RCTs).

These studies included follow-up periods lasting several years, focusing on measuring hospital admission rates due to heart failure and changes in patient daily functioning.


Q: Is Lanoxin MD considered a treatment for all types of heart failure?

Official labeling indicates the medicine is used for the treatment of mild to moderate heart failure.

Research has explored its evaluation in patients presenting with both reduced and preserved heart pumping strength.


Q: What is the main difference between how Lanoxin MD helps with heart failure and how it helps with atrial fibrillation?

The two main uses of the medicine involve different primary goals.

For heart failure, the primary action is to strengthen the heart's contraction to improve blood circulation. For atrial fibrillation, the primary goal is to control the heart rate by slowing the electrical signals through the heart's conduction system.


Q: How long does it typically take to feel the full effects of Lanoxin MD?

After the initial dose, a detectable effect may be noticed within 0.5 to 2 hours, with the maximum effect occurring within 2 to 6 hours.

However, achieving consistent therapeutic levels (steady-state) in the body may take between 1 to 3 weeks to achieve consistent levels.


Q: Does the brand or manufacturer of Lanoxin MD matter for treatment effectiveness?

Lanoxin MD (digoxin) is available in both brand and generic forms. Regulatory bodies require that generic products meet strict standards for bioequivalence.

This standard aims to achieve equivalent absorption and action to the brand-name product.


Q: Is there an official statement regarding alcohol consumption while taking Lanoxin MD?

Official regulatory information notes that it is unknown if drinking alcohol directly affects the drug's activity.

However, there is a risk that alcohol may increase certain central nervous system side effects such as dizziness and confusion.


Q: Can Lanoxin MD cause breast enlargement (gynecomastia) in males?

Gynecomastia (breast enlargement in males) has been occasionally observed as an adverse reaction in patients following the prolonged use of the medicine.


Q: What research exists about discontinuing Lanoxin MD after long-term use?

Studies have examined the effect of stopping the medicine in long-term users with heart failure. Studies have examined that the withdrawal of digoxin may be associated with patterns of worsening functional status and reduced exercise capacity.


Q: Is there a specific time of day recommended for taking Lanoxin MD for better absorption?

The medicine can be taken with or without food. It is generally recommended to take it at the same time each day to maintain consistent blood levels.

The focus is primarily on consistency rather than absorption at a specific time.

How should Lanoxin MD be stored and disposed of?

How to Store and Dispose of Lanoxin MD (Digoxin)

Lanoxin (digoxin) tablets must be stored according to regulatory specifications to ensure product integrity.


Storage Requirements

  • Temperature: Store at 25°C (77°F), with controlled excursions permitted between 15°C to 30°C (59°F to 86°F).
  • Protection: The medicine must be kept in a dry place and protected from light.
  • Container: Tablets should be stored in a tight, light-resistant container as defined by official pharmacopeial standards.
  • Child Safety: It is mandatory to keep out of reach of children.

Disposal Instructions

Unused or expired Lanoxin tablets should be disposed of through a drug take-back program or an authorized collector as the preferred method. If a take-back option is unavailable, the tablets must be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed container for household trash. Regulatory guidelines instruct that the product must not be flushed down a toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanoxin MD found in:

A-Z Index: